Information  X 
Enter a valid email address

Spinnaker Opports (KNB)

  Print      Mail a friend

Friday 19 July, 2019

Spinnaker Opports

Conditional Fundraise and Update on RTO

RNS Number : 0464G
Spinnaker Opportunities PLC
19 July 2019

19 July 2019

Spinnaker Opportunities plc

("Spinnaker" or the "Company")

£1.4 Million Conditional Fundraise

and Update on Proposed Medicinal Cannabis RTO


Further to the announcement on 26 February 2019 regarding the proposed reverse take-over of medicinal cannabis company, Kanabo Research Limited (the "RTO" or the "Proposed Acquisition"), the Company is pleased to announce the terms of a contractual investment commitment, via Peterhouse Capital Limited, for a maximum of £1.4 million (the "Investment Commitment") from a single professional investor, conditional on the completion of the Proposed Acquisition and admission to trading by an agreed long-stop date.

The review and approval process of the Prospectus (the "Prospectus") for the Proposed Acquisition is currently in progress. The Investment Commitment will be made on the terms and conditions summarised below. These will also be set out in the Prospectus.

Andy Morrison, Chairman of Spinnaker, said:

"We are delighted by the Investment Commitment that we have received for this ground-breaking acquisition, even ahead of any formal marketing process. We continue to work to deliver this acquisition to shareholders as soon as possible."

Avihu Tamir, Founder and CEO of Kanabo Research Limited, commented:

"It is hugely exciting that the acquisition by Spinnaker is progressing apace. The £1.4 million Investment Commitment is a great sign of confidence in the combination of Spinnaker and Kanabo."

"We believe that Spinnaker's public listing, combined with Kanabo's medical-grade vaporiser, research licences and patents and prospective equity interests in cultivation and production facilities, mean that the enlarged company will be well placed to take advantage of the burgeoning European medical cannabis market."

Investment Commitment - Principal Terms

Under the terms of the Investment Commitment the investor undertakes to participate, at the placing price, in a fund-raising to be conducted in conjunction with the Proposed Acquisition up to an investment amount representing a maximum of 4.99 per cent of the enlarged issued share capital immediately following completion of the Proposed Acquisition.

Any remaining balance of the £1.4 million Investment Commitment not utilised by the Company at completion of the RTO will be converted into a new nil-coupon, unsecured, Convertible Loan Note (the "CLN") to be issued by the Company. The CLN can only thereafter be converted, at the same price as the RTO placing, subject to such conversion not resulting in the investor holding more than 4.99 per cent of the enlarged issued share capital immediately following conversion.

In consideration of the Investment Commitment, which substantially underpins the minimum fund-raising required for the to-be enlarged company, the Company will pay a fee of 10 per cent of that part of the Investment Commitment that is taken up at completion.

For further information, please visit or contact the following:


Peterhouse Capital Limited (Financial Adviser and Joint Broker)

Tel: +44 (0)20 7469 0930

Lucy Williams / Guy Miller / Eran Zucker

SI Capital (Joint Broker)

Tel: +44 (0)1483 413 500 / +44 (0) 203 871 4038

Nick Emerson / Greg Mahoney

Blytheweigh (Financial PR)

Tel: +44 (0) 207 138 3553

Tim Blythe / Julia Tilley / Fergus Cowan / Jane Lenton


Notes to Editors

Kanabo develops, medically validates and patents formulas of medicinal cannabis as well as over-the-counter products. The company holds three licenses for cannabis research, two patents on its formulations, and has already conducted selected pre-clinical trials.

Kanabo also holds distribution rights for a pharmaceutical-grade vaporizer, which it has further developed to include metered dosage. This innovation enabled it to become the first medically approved vaporizer in the world. Kanabo has exclusive distribution rights to the vaporizer in Africa, Asia, the Middle East, and Europe.

Kanabo's supply chain includes prospective equity interests in several international cultivation and production facilities. Kanabo aims to bring operational expertise and management to these partners to ensure both steady biomass offtake and high-quality production of finished products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t